[The mechanisms of the neurotropic action of bromantan].
The main components of bromantan central neurotropic effect is its dopamine-positive activity: antagonism (5 mg/kg) to the effects of neuroleptics in rats, blocking (50 microM) of dopamine synaptosomal capture, and a complicated in structure influence on the serotoninergic mediator systems--inhibition of neuronal capture of serotonin (50 microM), behavior responses to 5-hydroxytryptophan (1-20 mg/kg) in mice, decrease in the mediator content in intact rat brain when administered in doses lower than 5 mg/kg, and the absence of this parameter with the use of higher doses. The central noradrenergic effect of the drug is less expressed: blocking of the synaptosomal capture of norepinephrine in higher (more than 500 microM) concentrations), and absence of an effect, in distinction from sydnocarb, 1-5 mg/kg, on the mediator content in intact rat brain. The drug (1-50 mg/kg, intravenously) has no effect on neuro-muscular transmission in cats and in higher doses (30-600 mg/kg) inhibits to a certain degree the central effects of nicotine and arecoline.
Morozov
I S
IS
Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia.
Pukhova
G S
GS
Avdulov
N A
NA
Sergeeva
S A
SA
Spasov
A A
AA
Iezhitsa
I N
IN
D000547:Amantadine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D001921:Brain / Q000187:drug effects; D002375:Catalepsy / Q000139:chemically induced; D002415:Cats; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D008297:Male; D051379:Mice; D011619:Psychotropic Drugs / Q000494:pharmacology*; D051381:Rats; D017981:Receptors, Neurotransmitter / Q000187:drug effects; D012640:Seizures / Q000139:chemically induced; D019956:Stereotypic Movement Disorder / Q000139:chemically induced
D011619:Psychotropic Drugs; D017981:Receptors, Neurotransmitter; D000547:Amantadine; C085955:bromantane